Hoth Therapeutics, Inc. (HOTH), a clinical-stage biopharmaceutical company, announced on Thursday that it has obtained Japan Country Patent No. 7677628 for its HT-KIT platform.
The patent was granted by the Japan Patent Office on May 7, 2025, providing exclusive protection through August 27, 2039.
The patent covers Hoth's novel approach using splice-switching oligonucleotides or SSOs to selectively disrupt KIT gene expression in mast cells, which are involved in conditions ranging from chronic hives to rare cancers.
This patent ensures long-term commercial exclusivity in the Japanese pharmaceutical market.
Robb Knie, CEO of Hoth Therapeutics, said, "Securing intellectual property protection in Japan—a globally significant pharmaceutical market—underscores the global value of HT-KIT. We see strategic licensing potential across Asia as we move this asset forward."
Hoth continues to seek strategic global partners, especially in Asia, to co-develop and commercialize HT-KIT and other innovative therapeutic platforms.
Currently, HOTH is trading at $1.40, up by 6.44 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.